GSA Capital Partners’s Madrigal Pharmaceuticals MDGL Stock Holding History
Bought
Maintained
Sold
Other funds holding MDGL
BBA
GSA Capital Partners's MDGL Position: Q3 2026 in Review
GSA Capital Partners reduced its Madrigal Pharmaceuticals (MDGL) stake by 23% in Q3 2026, selling an estimated $96.7K and leaving 606 shares worth $305K. The position accounts for 0.02% of the portfolio, ranked #1381.
GSA Capital Partners first reported a position in MDGL in Q1 2015 and has held it in 12 quarters since. The position peaked at $1.12M in Q4 2019. 437 funds tracked by Wall St. Rank hold MDGL as of Q3 2026.
- GSA Capital Partners held 606 shares of Madrigal Pharmaceuticals worth $305K as of Q3 2026.
- GSA Capital Partners sold 183 Madrigal Pharmaceuticals shares in Q3 2026, an estimated $96.7K.
- Madrigal Pharmaceuticals made up 0.02% of GSA Capital Partners's portfolio in Q3 2026, its #1381 holding.
- GSA Capital Partners first reported a position in Madrigal Pharmaceuticals in Q1 2015 and has held it in 12 quarters since.
- GSA Capital Partners's Madrigal Pharmaceuticals position peaked at $1.12M in Q4 2019.
- 437 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2026.
Based on GSA Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.